SCHEMBL19841237

SCHEMBL19841237

CC(O)(c1ccccc1)[C@H]1CCCN1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.70
CYP1A2 P05177 2/20 0.70
CYP2C19 P33261 2/20 0.70
KDM4E B2RXH2 1/20 0.70
NPC1 O15118 1/20 0.70
HPGD P15428 1/20 0.70
MAPK1 P28482 1/20 0.70
RAB9A P51151 1/20 0.70
LMNA P02545 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HRH1 P35367 1/20 0.43
SCN1A P35498 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14227426 1.00 CYP2D6 (0.70) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL14227427 1.00 CYP2D6 (0.70) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL16931709 1.00 CYP2D6 (0.70) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL16640675 1.00 CYP2D6 (0.70) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL3088977 1.00 CYP2D6 (0.70) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL20833321 1.00 CYP2D6 (0.70) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL20833053 0.95 CYP2D6 (0.63) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL20833279 0.95 CYP2D6 (0.63) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL20833147 0.95 CYP2D6 (0.63) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL20850797 0.93 CYP2D6 (0.61) CYP2D6CYP1A2CYP2C19KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718638-B2 Compounds, compositions and methods for synthesis WAVE LIFE SCIENCES LTD. (SG) 2023-08-08 US disclosed
US-11634710-B2 Oligonucleotide compositions and methods thereof WAVE LIFE SCIENCES LTD. (SG) 2023-04-25 US disclosed
EP-2872147-B1 METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES WAVE LIFE SCIENCES LTD (SG) 2022-12-21 EP disclosed
US-20220098585-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2022-03-31 US disclosed
US-20210130821-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2021-05-06 US disclosed
US-20210115444-A1 CHIRAL DESIGN WAVE LIFE SCIENCES LTD. (SG) 2021-04-22 US disclosed
US-20200299692-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2020-09-24 US disclosed
WO-2020191252-A1 TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2020-09-24 WO disclosed
US-20200231620-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2020-07-23 US disclosed
US-10590413-B2 Chiral control WAVE LIFE SCIENCES LTD. (SG) 2020-03-17 US disclosed
US-10428019-B2 Chiral auxiliaries WAVE LIFE SCIENCES LTD. (SG) 2019-10-01 US disclosed
US-9982257-B2 Chiral control WAVE LIFE SCIENCES LTD. (SG) 2018-05-29 US disclosed
US-9885037-B2 2018-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718638-B2 Compounds, compositions and methods for synthesis ALKBH1, DUT, RNGTT CYP2D6 888/4885CYP1A2 4059/4885CYP2C19 3230/4885
US-20210130821-A1 CHIRAL CONTROL RNGTT, POLI, NSUN3 CYP2D6 2805/4885CYP1A2 4590/4885CYP2C19 4466/4885
US-10428019-B2 Chiral auxiliaries PCNA, POLL, TYMP CYP2D6 554/4885CYP1A2 2690/4885CYP2C19 1300/4885
US-20200299692-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RBM17, HNRNPA2B1, HNRNPA1 CYP2D6 4249/4885CYP1A2 4864/4885CYP2C19 4869/4885
US-20200231620-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT CYP2D6 3929/4885CYP1A2 4658/4885CYP2C19 4618/4885
US-10590413-B2 Chiral control RNGTT, POLI, NSUN3 CYP2D6 2805/4885CYP1A2 4590/4885CYP2C19 4466/4885
US-11634710-B2 Oligonucleotide compositions and methods thereof RBM17, HNRNPA2B1, HNRNPA1 CYP2D6 4249/4885CYP1A2 4864/4885CYP2C19 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.